Amygdala Neurosciences Awarded $2.0 million NIH Grant to Conduct IND Enabling Studies

ANS-858, a new selective ALDH2 Inhibitor in pre-clinical development to reduce craving and relapse for patients being treated for alcohol and other substance use disorders. SAN FRANCISCO, Aug. 1, 2023 /PRNewswire/ — Amygdala Neurosciences (a private company) has been awarded a $2.0…

Click here to view original post


ADVERTISEMENT — Advertise With Biotech Networks